THIS PAPER presents information regarding rate of change of human femoral atherosclerosis during treatment of hyperlipoproteinemia. The estimates we report were obtained by assessment of two angiograms separated by an interval of approximately 13 months. Experiments of others with hyperlipoproteinemic animals suggest that change in fatty streaks can be detected in as short a period as eight months after alteration of lipid levels and is followed by change in more advanced plaques. To obtain this information, test and control animals have been sacrificed for direct examination of vessels at intervals after inducing or relieving hyperlipoproteinemia.' Directly comparable experiments are not possible in man and what is known of blood lipid effect on atherosclerosis has been deduced from a few studies employing angiography2-6 plus many studies where lesions have been evaluated indirectly through atherosclerosisrelated end points.
The rate of change of femoral atherosclerosis has been determined in 25 treated hyperlipoproteinemic patients. There were 13 Type 11 patients and 12 Type IV patients. Serial angiograms had been performed at an interval averaging 13 months. Film densities were analyzed by digital image processing to yield a computer estimate of atherosclerosis (CEA). Serial measurements of CEA on each patient were used to determine atherosclerosis percent change THIS PAPER presents information regarding rate of change of human femoral atherosclerosis during treatment of hyperlipoproteinemia. The estimates we report were obtained by assessment of two angiograms separated by an interval of approximately 13 months. Experiments of others with hyperlipoproteinemic animals suggest that change in fatty streaks can be detected in as short a period as eight months after alteration of lipid levels and is followed by change in more advanced plaques. To obtain this information, test and control animals have been sacrificed for direct examination of vessels at intervals after inducing or relieving hyperlipoproteinemia.' Directly comparable experiments are not possible in man and what is known of blood lipid effect on atherosclerosis has been deduced from a few studies employing angiography2-6 plus many studies where lesions have been evaluated indirectly through atherosclerosisrelated end points.
Interpretation of lipid lowering intervention trials, such as The Coronary Drug Project, Minnesota Coronary Survey, and Lipid Research Clinic Primary Prevention Trial, is ambiguous in regard to atherosclerosis change because myocardial infarction is the major end point studied. Myocardial infarction can occur when atherosclerosis becomes more severe and also when thrombosis is superimposed on unchanged atherosclerotic lesions. Myocardial infarction can occasionally occur when coronary arteries appear nor-mal. The occurrence of myocardial infarction implies that vascular insufficiency has grown worse. There is no corresponding end point which can imply that vascular insufficiency has improved. This makes intervention trials based on myocardial infarction insensitive to changes which might follow atherosclerosis improvement. More direct information regarding human atherosclerosis change is desirable and now can be obtained from femoral angiograms. The information we report here reflects directly measured change in lesion state with equal sensitivity to change in either direction -regression or progression. A limitation in interpreting the results we present is that the relationship of femoral lesion change to long-term cardiovascular mortality rate is not known.
In a previous report we presented evidence that femoral atherosclerosis as determined by angiography is common in young patients with hyperlipoproteinemia, although they may have few symptoms.7 We have also reported that the visible extent of vessel wall involvement diminished in nine of these patients among 25 treated for hyperlipoproteinemia and studied by serial angiography.8 In a separate series of reports we described development of an instrumental method to assess angiograms.9-1" This method involves converting an X-ray image recorded on film into a digital array for computer processing using an optical image dissector. Edges of the vessel image are located by analyzing digital data in lines perpendicular to the long axis of the vessel. Irregularities of each vessel edge and densities of the vessel image are analyzed further to provide assessment of atherosclerosis through a combined measure, CEA (computer estimated atherosclerosis), which has previously been calibrated directly against atherosclerosis determined at autopsy.9 In this report, CEA has been determined on all films previously assessed by human readers and used to estimate rate of change in atherosclerotic lesions for correla- CEA, X months between angiograms where CEA1 = CEA at angiogram #1, CEA2 = CEA at angiogram #2. CEA/age is an estimate of the rate at which atherosclerosis has accumulated during the life of each patient prior to the first angiogram. It is a means of adjusting the degree of atherosclerosis for the effect of age. CEA percent change per month expresses the rate of change in the period of therapy between angiograms. If change is in the direction of lesion regression, this rate has a negative sign. CEA percent change per month is strongly correlated, r = 0.931, with CEA percent change (the observed magnitude of change without regard to radiographic interval) because the interval between angiograms was relatively uniform. Conclusions reported for CEA percent change per month are identical to those observed for CEA percent change. Results Table 6 compares the two hyperlipoproteinemic types. There was no significant difference in percent change of CEA per month, CEA at first angiogram, or CEA/age. These data provide evidence that the severity of atherosclerosis in femoral segments analyzed in the two types was comparable and that no difference in rate of atherosclerosis accumulation in the period before the first angiogram was demonstrated. These data also indicate that average change rates in the two hyperlipoproteinemic types did not differ. Table 7 presents the spectrum of CEA percent change per month observed in our patients. These rates present an estimate of the average direction and magnitude of change during one month of therapy for each patient. It is clear that the response of atherosclerosis was heterogeneous. The average rate of change for the entire group did not differ from zero. One possible goal for medical therapy of atherosclerosis may be to stabilize existing lesions. If additional experience indicates that group average rates of atherosclerosis change do not differ from zero for prolonged periods, this can provide evidence for stability of lesion in an "average" individual in the group. Any value of therapy Current intervention studies of risk factor reduction in man which employ epidemiologic end points require large groups of study subjects to reduce the influence of individual variability. Serial comparison of each individual is not possible when some epidemiologic end points are employed, for example, cardiovascular death. Serial data are extremely difficult to evaluate with other epidemiological end points, such as myocardial infarction and stroke. We believe that the simplicity and strength of serial comparison of lesion size should be useful in atherosclerosis research and have developed angiography as the procedure for this.
The clinical study providing films for this examination was a pilot project to examine use of femoral angiography for atherosclerosis evaluation in hyperlipoproteinemic patients with no or only a few symptoms. The study included too few subjects and employed too many types of therapy to allow judgment regarding the efficacy of individual drugs and diet. However, it is of some interest to note that the magnitude of lipid lowering we have achieved was not greater than in a previous study where serial femoral angiograms showed no change in atherosclerosis.2 The angiographic technique we employed was a modification of conventional clinical procedures and had the specific goal of atherosclerosis assessment. This allowed recognition of smaller lesion change in our study and appears to be an important reason for our different result. It is also noteworthy that the changes reported have been observed in our films by two entirely separate procedures. First, we employed a systematic visual assessment by independent readers "blind" as to the sequence of films.8 Next, we employed an instrumental procedure which had been calibrated on femoral vessels removed at autopsy. 9 The results of both assessments are in general agreement in indicating that atherosclerosis regression can occur in humans. Not Our own studies and those of others have emphasized that the choice of a vasoactive agent in the critically ill patient frequently requires balancing cardiac and peripheral effects,'13-1 particularly in patients with decreased coronary wedge pressure and right atrial pressure decreased from 23 to 18 mm Hg (P < 0.05) and from 10 to 8 mm Hg (P < 0.01) respectively. Improvement in hemodynamic status by dopamine was associated with deterioration of myocardial metabolism. Myocardial oxygen extraction ratios and arterial-coronary sinus oxygen differences increased from 73 to 76% (P < 0.05) and from 13.02 to 14.19 ml/100 ml (P < 0.02) respectively. Myocardial lactate production increased from -8 to -15% (P = 0.05).
We conclude that dopamine improved cardiac performance at the expense of myocardial oxygenation and that dopamine is potentially harmful to actuely ischemic myocardium.
reserve. Beta-adrenergic stimulation by isoproterenol improves myocardial contractility and cardiac output but frequently increases myocardial oxygen requirements beyond that available. Alpha-adrenergic stimulation by 1-norepinephrine raises coronary perfusion pressure and enhances oxygen delivery to myocardium supplied by diseased coronary arteries, but reduces peripheral blood flow. Dopamine has been shown to maintain central aortic pressure at the same time that it augments renal and splanchnic perfusion by direct dilatation of those vascular beds.
This paper presents the effects of dopamine on the hemodynamic status and on myocardial metabolism in eight patients in shock associated with acute myocardial infarction. The study indicates that dopamine in the doses needed to increase peripheral perfusion and arterial blood pressure in these patients markedly increased myocardial oxygen consumption and led to deterioration of myocardial metabolism. For this reason, dopamine is potentially harmful to acutely ischemic myocardium.
Methods
Patients were considered for the present study if the criteria for left ventricular pump failure following acute myocardial infarction were present; a) absent or poor peripheral pulses; b) cold, clammy skin; c) intravascular
